Please login to the form below
Keytruda
This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.
Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
Elsewhere in its Q2 results, Merck saw sales growth for its blockbuster immunotherapy Keytruda, which grew by 23% to $4.2bn, reflecting continued demand in the major non-small cell lung
Latest news
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process. ... The Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process for the treatment of certain endometrial cancer patients.
-
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data. ... Among these, Keytruda achieved an overall response rate of just over 13% (19 patients), with a complete response rate of 1.4%.
-
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
Instead of targeting a specific genetic defect, Keytruda targets tumours that have a high degree of genetic instability. ... As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda
-
Merck’s Keytruda improves outcomes for metastatic cervical cancer patients
Keytruda improved overall survival and progression-free survival regardless of patients' PD-L1 status. ... Merck – known as MSD outside the US and Canada – has revealed positive results for its checkpoint inhibitor Keytruda in patients with persistent
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
Merck &Co – known as MSD outside the US and Canada – has announced that its PD-1 inhibitor Keytruda plus Eisai’s Lenvima improved outcomes versus Pfizer’s Sutent on a measure ... When administered alongside Lenvima, Keytruda demonstrated a
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
More from news
Approximately 168 fully matching, plus 277 partially matching documents found.
Latest Intelligence
-
Putting commercial intelligence at the heart of strategy
Merck Sharp &Dohme (MSD), the company that markets Keytruda, and Bristol-Myers Squibb (BMS), the company that markets Opdivo, approached development of their respective products in this area with starkly contrasting
-
20 for 2020 – Five pharma companies to watch
Opdivo is being squeezed out of the market by Merck &Co/ MSD’s Keytruda (pembrolizumab), which dominates the lucrative first-line NSCLC market and is cutting into BMS’ share of the ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor
-
25 Women Leaders in UK Healthcare
its role in developing immuno-oncology blockbuster Keytruda. ... The coming Keytruda windfall will also allow the charity to set up a stand-alone venture capital division, with which it could seed funding and help promote research in key areas.
-
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the
-
Immuno-oncology in 2019: the rapid evolution continues
PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.
Putting commercial intelligence at the heart of strategy
20 for 2020 – Five pharma companies to watch
25 Women Leaders in UK Healthcare
2019: CRISPR and therapeutic gene editing comes of age
Immuno-oncology in 2019: the rapid evolution continues
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Merck’s CEO Kenneth Frazier to retire after ten years in the role
Under his leadership, Merck has seen impressive growth for its immunotherapy blockbuster Keytruda (pembrolizumab) and other innovative treatments.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types. ... Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations,
-
BMS appoints new commercial leader, Davies joins Eisai and more
The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda.
Merck’s CEO Kenneth Frazier to retire after ten years in the role
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
BMS appoints new commercial leader, Davies joins Eisai and more
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
OncoSec’s intratumoral IL-12 EP platform not only enhances anti–PD-(L) 1 activity (currently treating anti-PD-1–refractory melanoma patients with pembrolizumab [Keytruda] plus its investigational TAVO in
-
Mastering the precision medicine opportunity
Last year the FDA made a pioneering move in this space and approved Keytruda for use in adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or
-
18 SWITCHED ONcology: The Big Communication
Here’s a look at Keytruda, the drug Jimmy Carter says made his tumors vanish.
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
However, hidden in the pipeline was the ‘miracle’ immuno-oncology drug Keytruda.
-
A stumble, but not a fall – what’s next for Opdivo?
Impressively, Opdivo consistently outperformed Merck &Co.'s ($MRK) Keytruda (pembrolizumab), racking up $1.58 billion in sales during the first half of 2016 compared to $563 million earned by its main ... Rubbing salt into BMS’s wounds, Merck's
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
PMHub
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
